{"ticker": {"uuid": "2775fd19-ed9e-4688-a78f-d99fb8e88ad7", "symbol": "CRDL", "name": "Cardiol Therapeutics Inc Class A", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcmd6ZkwwSVNIWlpsRjBTZmRSbm5sRjFjODFkT2M5Z1h5UkpUbmc1Nkt1Vm94VU5SWVZsT1NILTlMcklCN1dKdjlhM1gwWG91YUFSV3pEczZpOU5sM3RCUE5BdnpNZXhkT2xZMVZ3S1E1blE2UU43dEt1V1Myd0M4bUo0WmMxYUF1MVRCN2hROFdiU004NTZzRkdEajNuT21kNU9vUUg5X3NDSGN2X012NzBRZ2JxblZ2T3Bic3VDNUgxNm1JM19n?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T12:58:58+00:00", "published_display": "15 Jul 2026 12:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-phase-ii-recurrent-112700475.html", "source_name": "CNW Group", "published_at": "2026-07-14T11:27:00+00:00", "published_display": "14 Jul 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDL SEC Filings - Cardiol Therapeu 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1xU2VlTmlVeXNIUVlFTjIwTml6LTZOT2o1SE9lSnVNRkxtRzJvR1FCQ0hTNTJMeU1fVXlBQTNDejNFTkVCRXR6UGRzVloxYVZVOW5WSVdvMGZYdVF5N2piVDJjenZoZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T23:28:04+00:00", "published_display": "09 Jul 2026 23:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOdU01YmY4TjR5SlBCMUdDTzJmZEkyTzgyVDZHSmhRR3ZRcXl3SF9ibmhkc2swZVllRFZTX3JvcXJ6bXJDQWxSenVoMW00Y3ZKU2VIb1dlS3UzZ3RPekVORVJ1REN6QjRQaG8wVG9HbkFXZDFhZVk3ZHVvcFlwTC1WSEFuOVBMUGpFM1Yta0hjUGdka0dRbnlMb2dCdkV1UFBFMDZPZDAxcmw3b1o2ZTk4?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-09T13:20:39+00:00", "published_display": "09 Jul 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-participate-fireside-chat-112700456.html", "source_name": "PR Newswire", "published_at": "2026-07-09T11:27:00+00:00", "published_display": "09 Jul 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cardiol Therapeutics Inc. Class A Stocks", "summary": "This article lists ETFs that hold Cardiol Therapeutics Inc. Class A stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each fund. It highlights how these ETFs make stock investing more accessible and offer opportunities with lo", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDL/etfs/", "source_name": "TradingView", "published_at": "2026-07-07T16:13:22", "published_display": "07 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cardiol Therapeutics Inc. Class A \u2013 TSX:CRDL", "summary": "This article displays the \"Price to earnings forward\" metric for Cardiol Therapeutics Inc. Class A (TSX:CRDL). It indicates the value and change over a period, noting that the data is \"Made by humans\" and sourced from ICE Data Services and FactSet. The page is from TradingView an", "url": "https://www.tradingview.com/symbols/TSX-CRDL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:10:38", "published_display": "27 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cardiol Therapeutics Inc. Class A \u2013 TSX:CRDL", "summary": "The article focuses on the enterprise value to revenue forward for Cardiol Therapeutics Inc. Class A (TSX: CRDL). It seems to be a financial data point provided by TradingView, indicating a key metric for the company's valuation. However, the provided content mainly consists of n", "url": "https://www.tradingview.com/symbols/TSX-CRDL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:49", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Inc. Class A Actuals & Estimates (TSX:CRDL)", "summary": "This article provides an overview of Cardiol Therapeutics Inc. Class A (TSX:CRDL) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings per share and revenue, and answers frequently ask", "url": "https://www.tradingview.com/symbols/TSX-CRDL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:11:18", "published_display": "26 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Inc. Class A Actuals & Estimates (NEO:CRDL)", "summary": "This article provides an overview of Cardiol Therapeutics Inc. Class A (CRDL) stock performance, including current trading price, historical highs and lows, market capitalization, and analyst forecasts. It also covers the company's financial results, such as recent earnings per s", "url": "https://www.tradingview.com/symbols/NEO-CRDL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:49", "published_display": "26 Jun 2026 08:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cardiol Therapeutics Inc. Class A (CRDL) stock, including analyst price targets, historical performance, and key financial data. It highlights that analysts have a maximum price target of 12.30 CAD and a minimum of 6.83 CAD for CRDL. The compa", "url": "https://www.tradingview.com/symbols/TSX-CRDL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:09:53", "published_display": "25 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2PA9E Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Cardiol Therapeutics Inc. (A2PA9E) shows a current stock price of 0.9160 EUR, having decreased by 2.97% in 24 hours. Analysts provide a price target forecast with a maximum estimate of 7.69 EUR and a minimum of 4.27 EUR. The company's next earnings report is expected on August 17", "url": "https://www.tradingview.com/symbols/LS-A2PA9E/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T12:10:52", "published_display": "25 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong shareholder support at Cardiol Therapeutics (CRDL) 2026 AGM as all directors elected", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVGNVWE1UQllqUUlRSVF3Z2tZVnJoMFc1bWItUjY1ZGJOeHNnVnVNV1JKVEphZzhhUWY0YVNPcXoxb0thQ2JtMW1WRDBUZVB1c1N2M0ppMjRoQmp2bWJOSDV3SFZHbzhKZXQwb2VWZ250NTZiUjNqUkdvdURVdHdUMkFKajVGZTJydkp1Ml9sSVZ4enE1blZjQ2xIb0ZsZnlMOHBsMVFtNXE0VUFNd2NpZ1lpbi1yUXQwdzRHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPVkI5cmhlM3NRR0N5V0xKWU9NZmhoN1Y5YkZDNUZmek1jWlpYbUpMNzNrbC0wUTZXRE1OMXotX0V0QkdXbUZZaVBUYnFwRXM4Q0R3cW1oOVd2aFJYR29LTTFXTURHaDQ3QmxtN3VHcXJSQlhEWVpNVllfQ2dybVlpMDFLeXozNThWaHpkc2RTNDZ0OVlPMWk0dml0LVd2akhwb29hRXlvcFhKYVFnbFlFU0FQTGlkeEJvMU80eUFXNzdUeFRwQ0tGOEh4YUZlSEcxVWZsMnd3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol shareholders back all AGM resolutions, elect 8 directors", "summary": "Cardiol Therapeutics Inc. announced that its shareholders approved all management resolutions at the 2026 Annual General Meeting held virtually on June 24, 2026. This included the election of eight directors with overwhelming support (between 96.24% and 99.19% of votes cast) and ", "url": "https://www.stocktitan.net/news/CRDL/cardiol-therapeutics-reports-results-of-2026-annual-general-meeting-656rts8o193d.html", "source_name": "Stock Titan", "published_at": "2026-06-25T07:27:00", "published_display": "25 Jun 2026 07:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders", "summary": "Cardiol Therapeutics announced the results of its 2026 Annual General Meeting of Shareholders, held on June 21, 2026. Shareholders re-elected four directors to the Board and approved the re-appointment of KPMG LLP as the company's auditors for the upcoming fiscal year. Additional", "url": "https://www.moomoo.com/news/post/72033817/press-release-cardiol-therapeutics-reports-results-of-2026-annual-general", "source_name": "Moomoo", "published_at": "2026-06-24T15:12:15", "published_display": "24 Jun 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-webcast-virtual-annual-112700044.html", "source_name": "CNW Group", "published_at": "2026-06-23T11:27:00+00:00", "published_display": "23 Jun 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) Slides 3.5% as Shares Approach Key Support Zone - Low Volume Node", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNa0hzTE9vU3NMWEU3aEhxTjJDMmk4UFhWYTJYRzJZalNlZl9uc3g3SE1kNkNfY0d1NVhjS1hRNTdELWo0eEFJZ3JDQjA2TzRYZUd2Q0hteEQxM2d2ZE5rSVM0Q0RPLXYxdEJiZXVnZGRlNW9KZXVTR0JBYVFxODdFejVYc1JFZ0N5ZXZ3UUxTQ1lOV1N6aEc4OTJWdmlpS2pZMllWak9uamJnV1c2R1FRNUtrMFNkdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ", "summary": "Cardiol Therapeutics Inc. will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ on May 19, 2026. The company, a late-stage life sciences firm, is focused on developing anti-inflammatory and anti-fibrotic therapies for h", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-participate-fireside-chat-112700254.html", "source_name": "Market source", "published_at": "2026-05-21T06:09:40", "published_display": "21 May 2026 06:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure", "summary": "MMCAP International Inc. SPC and MM Asset Management Inc. have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Cardiol Therapeutics Inc., reporting shared beneficial ownership of 21,063,856 Class A Common Shares, which represents 17.9% of the class as of March", "url": "https://www.stocktitan.net/sec-filings/CRDL/schedule-13g-a-cardiol-therapeutics-inc-amended-passive-investment-di-aaf1dc265d8f.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:39:16", "published_display": "15 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQcFVTZHF1Ty1SYkxkVGE0dm5qM0Z1dnZkdnQ2aXRfYjhXd3dRMTdIQ1hQQ19PRng3cVlMZHB4RGJ6d3VyR2I5RG5KR01aY0czblJfSkZLcTl5NWhzcEhnVEdfZ3RDcFUwQ3B4MFd6VkROZWxWM3JaVDh0V3BVcjZORVNVZExaaFNjZUVGcUF4WWxheUtoekdkcV9DUm4?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Inc. - Class A Common Shares (NQ: CRDL)", "summary": "This article provides news headlines related to Cardiol Therapeutics Inc. (Nasdaq: CRDL). Key updates include the FDA approving Cardiol's Investigational New Drug application for CardiolRx to test an oral cannabidiol formulation in acute myocarditis patients, and the company's st", "url": "https://markets.financialcontent.com/stocks/quote/news?Language=english%2F1000&Symbol=NQ%3ACRDL&CurrentPage=3", "source_name": "FinancialContent", "published_at": "2026-05-15T04:39:44", "published_display": "15 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-phase-ii-maveric-112700976.html", "source_name": "CNW Group", "published_at": "2026-05-07T11:27:00+00:00", "published_display": "07 May 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-us-premarket-expands-120756014.html", "source_name": "MT Newswires", "published_at": "2026-04-28T12:07:56+00:00", "published_display": "28 Apr 2026 12:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-expands-u-maveric-112700888.html", "source_name": "PR Newswire", "published_at": "2026-04-28T11:27:00+00:00", "published_display": "28 Apr 2026 11:27", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol plans 7 more U.S. sites for heart-drug trial at 75% enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPeXdpX3hRd2pKVndmTEZzTjdtT2R0dTJqU0FIZVh0cTFGM3dPQ1k5S1VCcTFiT3F0aFdUWEtaeW5wS294RXZiNWJ4VUhyYks2RVdsRnZnY0h3aVlnQThjYUs5QVNDcUZJSW1EeW1JWHFxOEYyOTNVYnVqVWNnMS1xTWZuT0JIS3pxS0hwOHJuYkJzblZUNXBvWmd2Tjd1U1FtTVZONTBjVFJoaHZ4bm9jY293UjI3b0JmRzZVdTZzWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart", "summary": "Cardiol Therapeutics will participate in a live interview with Barchart on April 14, 2026, to discuss its MAVERIC Phase III trial for recurrent pericarditis and results from the ARCHER Phase II trial for acute myocarditis. The interview will feature Cardiol's President and CEO, D", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-highlight-maveric-phase-112700600.html", "source_name": "Market source", "published_at": "2026-04-16T02:39:16", "published_display": "16 Apr 2026 02:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders", "summary": "Cardiol Therapeutics has announced that its Annual General Meeting of Shareholders will be held on June 24, 2026, with May 7, 2026, set as the record date for voting eligibility. The company, a foreign private issuer reporting under Form 40-F, also detailed its use of notice-and-", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CRDL/pressreleases/1258795/cardiol-therapeutics-sets-june-24-2026-date-for-annual-general-meeting-of-shareholders/", "source_name": "The Globe and Mail", "published_at": "2026-04-12T01:39:58", "published_display": "12 Apr 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date", "summary": "Cardiol Therapeutics Inc. (CRDL) has scheduled its Annual General Meeting (AGM) for June 24, 2026, with a record date of May 7, 2026, for both notice and voting rights as well as determining beneficial ownership. The meeting will involve holders of Class A Common shares and will ", "url": "https://www.stocktitan.net/sec-filings/CRDL/6-k-cardiol-therapeutics-inc-current-report-foreign-issuer-84e1559e0faf.html", "source_name": "Stock Titan", "published_at": "2026-04-10T17:09:43", "published_display": "10 Apr 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results", "summary": "Cardiol Therapeutics Inc. has filed its Annual Report on Form 40-F, which includes its audited financial statements for the fiscal year ended December 31, 2025. The report indicates 100,257,009 shares outstanding and confirms that management assessed internal controls as effectiv", "url": "https://www.stocktitan.net/sec-filings/CRDL/40-f-cardiol-therapeutics-inc-annual-report-canadian-issuer-24488d45a93b.html", "source_name": "Stock Titan", "published_at": "2026-04-01T09:09:35", "published_display": "01 Apr 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heart drug trial passes halfway mark as Cardiol funds work into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPZTZvamlvU19OVmwtZkNxUVFjNWlsUGNQNV9PREk3Z1lUY1Y1OGpURExHMWMwMVAxc0ZETXBQNzFYdkRMcUhRQWRvSW0wTzFFUHE3MHR4Y2lDVkdSdzItd3kzdnNoOV95RnNOOUpGNDV5b3Rpa0ZiN0lmZTN1VkptcEp0SGpOM2hZQkFYS0hVUDFuOXhjaU9iSWRVNmRmTjVXMDY3TE45aVVGMVl2dUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taxes of Cardiol Therapeutics Inc. Class A \u2013 HAM:CT9", "summary": "This article displays tax information for Cardiol Therapeutics Inc. Class A (HAM:CT9). It includes a table with period, value, change, and change percentage data, set against the backdrop of TradingView's financial data and tools. The page seems to be a financial data presentatio", "url": "https://www.tradingview.com/symbols/HAM-CT9/financials-income-statement/income-tax/", "source_name": "TradingView", "published_at": "2026-03-26T19:09:44", "published_display": "26 Mar 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference", "summary": "Cardiol Therapeutics presented at TD Cowen's 46th Annual Healthcare Conference, highlighting the accelerated enrollment of its Phase III MAVERIC study for CardiolRx in recurrent pericarditis, with top-line results expected in the second half of the year. The company emphasized th", "url": "https://finance.yahoo.com/news/cardiol-therapeutics-touts-phase-iii-230226821.html", "source_name": "Market source", "published_at": "2026-03-08T15:12:15", "published_display": "08 Mar 2026 15:12", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference", "summary": "Cardiol Therapeutics will present updates on its cardiovascular pipeline at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will highlight progress in its Phase III MAVERIC trial and Phase II ARCHER study, as well as the development of CRD-38. D", "url": "https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-to-present-cardiovascular-pipeline-update-at-td-cowen-health-care-conference", "source_name": "TipRanks", "published_at": "2026-02-25T14:51:41", "published_display": "25 Feb 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (NASDAQ:CRDL) Receives \"Buy\" Rating from HC Wainwright", "summary": "HC Wainwright reaffirmed a \"Buy\" rating for Cardiol Therapeutics (CRDL), setting a $9.00 price target. The company's lead product, CardiolRx, a CBD-based therapeutic, is in clinical development for myocardial protection and heart failure, with Phase 2 data already reported. Insti", "url": "https://www.marketbeat.com/instant-alerts/cardiol-therapeutics-nasdaqcrdl-receives-buy-rating-from-hc-wainwright-2026-02-10/", "source_name": "MarketBeat", "published_at": "2026-02-14T17:53:03", "published_display": "14 Feb 2026 17:53", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myocarditis trial finds CardiolRx reduced heart swelling marker", "summary": "Cardiol Therapeutics announced the publication of its Phase II ARCHER study results in ESC Heart Failure, revealing that CardiolRx significantly reduced left ventricular mass and showed favorable trends in myocardial inflammation markers in 109 patients with acute myocarditis. Th", "url": "https://www.stocktitan.net/news/CRDL/cardiol-therapeutics-archer-phase-ii-study-results-published-in-esc-uaew1cau6x2o.html", "source_name": "Stock Titan", "published_at": "2026-02-11T11:27:59", "published_display": "11 Feb 2026 11:27", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at Brookline Capital Management", "summary": "Brookline Capital Management has upgraded Cardiol Therapeutics (NASDAQ:CRDL) to a \"strong-buy\" rating. The company, which specializes in immunomodulatory cardiovascular therapies, reported quarterly EPS of ($0.09) and has an average target price of $9.00 from analysts, indicating", "url": "https://www.marketbeat.com/instant-alerts/cardiol-therapeutics-nasdaqcrdl-raised-to-strong-buy-at-brookline-capital-management-2026-02-05/", "source_name": "MarketBeat", "published_at": "2026-02-06T14:52:19", "published_display": "06 Feb 2026 14:52", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders", "summary": "Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the compa", "url": "https://finance.yahoo.com/news/cardiol-therapeutics-reports-results-2025-112700680.html", "source_name": "Market source", "published_at": "2026-02-01T00:32:36", "published_display": "01 Feb 2026 00:32", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing", "summary": "Cardiol Therapeutics has secured approximately $14.85 million through a bought-deal private placement. The financing involves issuing 11.4 million units at $1.30 per unit, each including one common share and a half-warrant exercisable at $1.75. This move aims to strengthen the co", "url": "https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-secures-14-85-million-bought-deal-unit-financing", "source_name": "TipRanks", "published_at": "2026-01-29T11:27:58", "published_display": "29 Jan 2026 11:27", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOTW1hcHZDMzN4dEU1TmNEcFJ0cnZsMVo3eUJONmZxMWoyM1BsWXlzUEdDRFQ1RjktMy0xRVdXcWJKWXJmSzE3RmgtYnhSaGhNYVRkWC10QVZLOU9WMVo5ekxHZUlBUkIydlRwSndKOVZVbUhTSnI0RzMxR1pucldmX1BvbnlHdjV0NXVTYnJnU0thdGNHMUJZ?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQd2JTakl5dzA3czNfYVctbUJUTDMwMzBDY0c2eVc3T1NMczBfaFd1eFVDMEc2R21CdENmSEZPdGlMdFhreTBOM3pEQktCNW5hTko5bzZZQXNqdTNzZzhwMFF6NEY2dFlXakJSYmhkVld4TkQ4SzN5U0U2dDRIRm40VlVweVlZWnpRUFE2eGRlMzJ5SGo5QlVyYkw4QnE4MWo5bm1oWTU0bmVpcnZWdXhkbG1pNFYzLWhfZ3VwekRBVmd6djJhSUdDRWQ1OWhVMFVVbkE?oc=5", "source_name": "TMX Newsfile", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQcmd6ZkwwSVNIWlpsRjBTZmRSbm5sRjFjODFkT2M5Z1h5UkpUbmc1Nkt1Vm94VU5SWVZsT1NILTlMcklCN1dKdjlhM1gwWG91YUFSV3pEczZpOU5sM3RCUE5BdnpNZXhkT2xZMVZ3S1E1blE2UU43dEt1V1Myd0M4bUo0WmMxYUF1MVRCN2hROFdiU004NTZzRkdEajNuT21kNU9vUUg5X3NDSGN2X012NzBRZ2JxblZ2T3Bic3VDNUgxNm1JM19n?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-15T12:58:58+00:00", "published_display": "15 Jul 2026 12:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-phase-ii-recurrent-112700475.html", "source_name": "CNW Group", "published_at": "2026-07-14T11:27:00+00:00", "published_display": "14 Jul 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDL SEC Filings - Cardiol Therapeu 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1xU2VlTmlVeXNIUVlFTjIwTml6LTZOT2o1SE9lSnVNRkxtRzJvR1FCQ0hTNTJMeU1fVXlBQTNDejNFTkVCRXR6UGRzVloxYVZVOW5WSVdvMGZYdVF5N2piVDJjenZoZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T23:28:04+00:00", "published_display": "09 Jul 2026 23:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) to Attend B. Riley Securities Summit in Boston", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOdU01YmY4TjR5SlBCMUdDTzJmZEkyTzgyVDZHSmhRR3ZRcXl3SF9ibmhkc2swZVllRFZTX3JvcXJ6bXJDQWxSenVoMW00Y3ZKU2VIb1dlS3UzZ3RPekVORVJ1REN6QjRQaG8wVG9HbkFXZDFhZVk3ZHVvcFlwTC1WSEFuOVBMUGpFM1Yta0hjUGdka0dRbnlMb2dCdkV1UFBFMDZPZDAxcmw3b1o2ZTk4?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-09T13:20:39+00:00", "published_display": "09 Jul 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-participate-fireside-chat-112700456.html", "source_name": "PR Newswire", "published_at": "2026-07-09T11:27:00+00:00", "published_display": "09 Jul 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cardiol Therapeutics Inc. Class A Stocks", "summary": "This article lists ETFs that hold Cardiol Therapeutics Inc. Class A stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each fund. It highlights how these ETFs make stock investing more accessible and offer opportunities with lo", "url": "https://www.tradingview.com/symbols/NASDAQ-CRDL/etfs/", "source_name": "TradingView", "published_at": "2026-07-07T16:13:22", "published_display": "07 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cardiol Therapeutics Inc. Class A \u2013 TSX:CRDL", "summary": "This article displays the \"Price to earnings forward\" metric for Cardiol Therapeutics Inc. Class A (TSX:CRDL). It indicates the value and change over a period, noting that the data is \"Made by humans\" and sourced from ICE Data Services and FactSet. The page is from TradingView an", "url": "https://www.tradingview.com/symbols/TSX-CRDL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:10:38", "published_display": "27 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cardiol Therapeutics Inc. Class A \u2013 TSX:CRDL", "summary": "The article focuses on the enterprise value to revenue forward for Cardiol Therapeutics Inc. Class A (TSX: CRDL). It seems to be a financial data point provided by TradingView, indicating a key metric for the company's valuation. However, the provided content mainly consists of n", "url": "https://www.tradingview.com/symbols/TSX-CRDL/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:49", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Inc. Class A Actuals & Estimates (TSX:CRDL)", "summary": "This article provides an overview of Cardiol Therapeutics Inc. Class A (TSX:CRDL) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings per share and revenue, and answers frequently ask", "url": "https://www.tradingview.com/symbols/TSX-CRDL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T11:11:18", "published_display": "26 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Inc. Class A Actuals & Estimates (NEO:CRDL)", "summary": "This article provides an overview of Cardiol Therapeutics Inc. Class A (CRDL) stock performance, including current trading price, historical highs and lows, market capitalization, and analyst forecasts. It also covers the company's financial results, such as recent earnings per s", "url": "https://www.tradingview.com/symbols/NEO-CRDL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:49", "published_display": "26 Jun 2026 08:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRDL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cardiol Therapeutics Inc. Class A (CRDL) stock, including analyst price targets, historical performance, and key financial data. It highlights that analysts have a maximum price target of 12.30 CAD and a minimum of 6.83 CAD for CRDL. The compa", "url": "https://www.tradingview.com/symbols/TSX-CRDL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T22:09:53", "published_display": "25 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2PA9E Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Cardiol Therapeutics Inc. (A2PA9E) shows a current stock price of 0.9160 EUR, having decreased by 2.97% in 24 hours. Analysts provide a price target forecast with a maximum estimate of 7.69 EUR and a minimum of 4.27 EUR. The company's next earnings report is expected on August 17", "url": "https://www.tradingview.com/symbols/LS-A2PA9E/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T12:10:52", "published_display": "25 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strong shareholder support at Cardiol Therapeutics (CRDL) 2026 AGM as all directors elected", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVGNVWE1UQllqUUlRSVF3Z2tZVnJoMFc1bWItUjY1ZGJOeHNnVnVNV1JKVEphZzhhUWY0YVNPcXoxb0thQ2JtMW1WRDBUZVB1c1N2M0ppMjRoQmp2bWJOSDV3SFZHbzhKZXQwb2VWZ250NTZiUjNqUkdvdURVdHdUMkFKajVGZTJydkp1Ml9sSVZ4enE1blZjQ2xIb0ZsZnlMOHBsMVFtNXE0VUFNd2NpZ1lpbi1yUXQwdzRHdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPVkI5cmhlM3NRR0N5V0xKWU9NZmhoN1Y5YkZDNUZmek1jWlpYbUpMNzNrbC0wUTZXRE1OMXotX0V0QkdXbUZZaVBUYnFwRXM4Q0R3cW1oOVd2aFJYR29LTTFXTURHaDQ3QmxtN3VHcXJSQlhEWVpNVllfQ2dybVlpMDFLeXozNThWaHpkc2RTNDZ0OVlPMWk0dml0LVd2akhwb29hRXlvcFhKYVFnbFlFU0FQTGlkeEJvMU80eUFXNzdUeFRwQ0tGOEh4YUZlSEcxVWZsMnd3?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol shareholders back all AGM resolutions, elect 8 directors", "summary": "Cardiol Therapeutics Inc. announced that its shareholders approved all management resolutions at the 2026 Annual General Meeting held virtually on June 24, 2026. This included the election of eight directors with overwhelming support (between 96.24% and 99.19% of votes cast) and ", "url": "https://www.stocktitan.net/news/CRDL/cardiol-therapeutics-reports-results-of-2026-annual-general-meeting-656rts8o193d.html", "source_name": "Stock Titan", "published_at": "2026-06-25T07:27:00", "published_display": "25 Jun 2026 07:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders", "summary": "Cardiol Therapeutics announced the results of its 2026 Annual General Meeting of Shareholders, held on June 21, 2026. Shareholders re-elected four directors to the Board and approved the re-appointment of KPMG LLP as the company's auditors for the upcoming fiscal year. Additional", "url": "https://www.moomoo.com/news/post/72033817/press-release-cardiol-therapeutics-reports-results-of-2026-annual-general", "source_name": "Moomoo", "published_at": "2026-06-24T15:12:15", "published_display": "24 Jun 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-webcast-virtual-annual-112700044.html", "source_name": "CNW Group", "published_at": "2026-06-23T11:27:00+00:00", "published_display": "23 Jun 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) Slides 3.5% as Shares Approach Key Support Zone - Low Volume Node", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNa0hzTE9vU3NMWEU3aEhxTjJDMmk4UFhWYTJYRzJZalNlZl9uc3g3SE1kNkNfY0d1NVhjS1hRNTdELWo0eEFJZ3JDQjA2TzRYZUd2Q0hteEQxM2d2ZE5rSVM0Q0RPLXYxdEJiZXVnZGRlNW9KZXVTR0JBYVFxODdFejVYc1JFZ0N5ZXZ3UUxTQ1lOV1N6aEc4OTJWdmlpS2pZMllWak9uamJnV1c2R1FRNUtrMFNkdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ", "summary": "Cardiol Therapeutics Inc. will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ on May 19, 2026. The company, a late-stage life sciences firm, is focused on developing anti-inflammatory and anti-fibrotic therapies for h", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-participate-fireside-chat-112700254.html", "source_name": "Market source", "published_at": "2026-05-21T06:09:40", "published_display": "21 May 2026 06:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure", "summary": "MMCAP International Inc. SPC and MM Asset Management Inc. have filed an amended passive investment disclosure (SCHEDULE 13G/A) for Cardiol Therapeutics Inc., reporting shared beneficial ownership of 21,063,856 Class A Common Shares, which represents 17.9% of the class as of March", "url": "https://www.stocktitan.net/sec-filings/CRDL/schedule-13g-a-cardiol-therapeutics-inc-amended-passive-investment-di-aaf1dc265d8f.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:39:16", "published_display": "15 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQcFVTZHF1Ty1SYkxkVGE0dm5qM0Z1dnZkdnQ2aXRfYjhXd3dRMTdIQ1hQQ19PRng3cVlMZHB4RGJ6d3VyR2I5RG5KR01aY0czblJfSkZLcTl5NWhzcEhnVEdfZ3RDcFUwQ3B4MFd6VkROZWxWM3JaVDh0V3BVcjZORVNVZExaaFNjZUVGcUF4WWxheUtoekdkcV9DUm4?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Inc. - Class A Common Shares (NQ: CRDL)", "summary": "This article provides news headlines related to Cardiol Therapeutics Inc. (Nasdaq: CRDL). Key updates include the FDA approving Cardiol's Investigational New Drug application for CardiolRx to test an oral cannabidiol formulation in acute myocarditis patients, and the company's st", "url": "https://markets.financialcontent.com/stocks/quote/news?Language=english%2F1000&Symbol=NQ%3ACRDL&CurrentPage=3", "source_name": "FinancialContent", "published_at": "2026-05-15T04:39:44", "published_display": "15 May 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-phase-ii-maveric-112700976.html", "source_name": "CNW Group", "published_at": "2026-05-07T11:27:00+00:00", "published_display": "07 May 2026 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-us-premarket-expands-120756014.html", "source_name": "MT Newswires", "published_at": "2026-04-28T12:07:56+00:00", "published_display": "28 Apr 2026 12:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-expands-u-maveric-112700888.html", "source_name": "PR Newswire", "published_at": "2026-04-28T11:27:00+00:00", "published_display": "28 Apr 2026 11:27", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol plans 7 more U.S. sites for heart-drug trial at 75% enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPeXdpX3hRd2pKVndmTEZzTjdtT2R0dTJqU0FIZVh0cTFGM3dPQ1k5S1VCcTFiT3F0aFdUWEtaeW5wS294RXZiNWJ4VUhyYks2RVdsRnZnY0h3aVlnQThjYUs5QVNDcUZJSW1EeW1JWHFxOEYyOTNVYnVqVWNnMS1xTWZuT0JIS3pxS0hwOHJuYkJzblZUNXBvWmd2Tjd1U1FtTVZONTBjVFJoaHZ4bm9jY293UjI3b0JmRzZVdTZzWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart", "summary": "Cardiol Therapeutics will participate in a live interview with Barchart on April 14, 2026, to discuss its MAVERIC Phase III trial for recurrent pericarditis and results from the ARCHER Phase II trial for acute myocarditis. The interview will feature Cardiol's President and CEO, D", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cardiol-therapeutics-highlight-maveric-phase-112700600.html", "source_name": "Market source", "published_at": "2026-04-16T02:39:16", "published_display": "16 Apr 2026 02:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders", "summary": "Cardiol Therapeutics has announced that its Annual General Meeting of Shareholders will be held on June 24, 2026, with May 7, 2026, set as the record date for voting eligibility. The company, a foreign private issuer reporting under Form 40-F, also detailed its use of notice-and-", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CRDL/pressreleases/1258795/cardiol-therapeutics-sets-june-24-2026-date-for-annual-general-meeting-of-shareholders/", "source_name": "The Globe and Mail", "published_at": "2026-04-12T01:39:58", "published_display": "12 Apr 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date", "summary": "Cardiol Therapeutics Inc. (CRDL) has scheduled its Annual General Meeting (AGM) for June 24, 2026, with a record date of May 7, 2026, for both notice and voting rights as well as determining beneficial ownership. The meeting will involve holders of Class A Common shares and will ", "url": "https://www.stocktitan.net/sec-filings/CRDL/6-k-cardiol-therapeutics-inc-current-report-foreign-issuer-84e1559e0faf.html", "source_name": "Stock Titan", "published_at": "2026-04-10T17:09:43", "published_display": "10 Apr 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results", "summary": "Cardiol Therapeutics Inc. has filed its Annual Report on Form 40-F, which includes its audited financial statements for the fiscal year ended December 31, 2025. The report indicates 100,257,009 shares outstanding and confirms that management assessed internal controls as effectiv", "url": "https://www.stocktitan.net/sec-filings/CRDL/40-f-cardiol-therapeutics-inc-annual-report-canadian-issuer-24488d45a93b.html", "source_name": "Stock Titan", "published_at": "2026-04-01T09:09:35", "published_display": "01 Apr 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heart drug trial passes halfway mark as Cardiol funds work into 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPZTZvamlvU19OVmwtZkNxUVFjNWlsUGNQNV9PREk3Z1lUY1Y1OGpURExHMWMwMVAxc0ZETXBQNzFYdkRMcUhRQWRvSW0wTzFFUHE3MHR4Y2lDVkdSdzItd3kzdnNoOV95RnNOOUpGNDV5b3Rpa0ZiN0lmZTN1VkptcEp0SGpOM2hZQkFYS0hVUDFuOXhjaU9iSWRVNmRmTjVXMDY3TE45aVVGMVl2dUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taxes of Cardiol Therapeutics Inc. Class A \u2013 HAM:CT9", "summary": "This article displays tax information for Cardiol Therapeutics Inc. Class A (HAM:CT9). It includes a table with period, value, change, and change percentage data, set against the backdrop of TradingView's financial data and tools. The page seems to be a financial data presentatio", "url": "https://www.tradingview.com/symbols/HAM-CT9/financials-income-statement/income-tax/", "source_name": "TradingView", "published_at": "2026-03-26T19:09:44", "published_display": "26 Mar 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference", "summary": "Cardiol Therapeutics presented at TD Cowen's 46th Annual Healthcare Conference, highlighting the accelerated enrollment of its Phase III MAVERIC study for CardiolRx in recurrent pericarditis, with top-line results expected in the second half of the year. The company emphasized th", "url": "https://finance.yahoo.com/news/cardiol-therapeutics-touts-phase-iii-230226821.html", "source_name": "Market source", "published_at": "2026-03-08T15:12:15", "published_display": "08 Mar 2026 15:12", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference", "summary": "Cardiol Therapeutics will present updates on its cardiovascular pipeline at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will highlight progress in its Phase III MAVERIC trial and Phase II ARCHER study, as well as the development of CRD-38. D", "url": "https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-to-present-cardiovascular-pipeline-update-at-td-cowen-health-care-conference", "source_name": "TipRanks", "published_at": "2026-02-25T14:51:41", "published_display": "25 Feb 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (NASDAQ:CRDL) Receives \"Buy\" Rating from HC Wainwright", "summary": "HC Wainwright reaffirmed a \"Buy\" rating for Cardiol Therapeutics (CRDL), setting a $9.00 price target. The company's lead product, CardiolRx, a CBD-based therapeutic, is in clinical development for myocardial protection and heart failure, with Phase 2 data already reported. Insti", "url": "https://www.marketbeat.com/instant-alerts/cardiol-therapeutics-nasdaqcrdl-receives-buy-rating-from-hc-wainwright-2026-02-10/", "source_name": "MarketBeat", "published_at": "2026-02-14T17:53:03", "published_display": "14 Feb 2026 17:53", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myocarditis trial finds CardiolRx reduced heart swelling marker", "summary": "Cardiol Therapeutics announced the publication of its Phase II ARCHER study results in ESC Heart Failure, revealing that CardiolRx significantly reduced left ventricular mass and showed favorable trends in myocardial inflammation markers in 109 patients with acute myocarditis. Th", "url": "https://www.stocktitan.net/news/CRDL/cardiol-therapeutics-archer-phase-ii-study-results-published-in-esc-uaew1cau6x2o.html", "source_name": "Stock Titan", "published_at": "2026-02-11T11:27:59", "published_display": "11 Feb 2026 11:27", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at Brookline Capital Management", "summary": "Brookline Capital Management has upgraded Cardiol Therapeutics (NASDAQ:CRDL) to a \"strong-buy\" rating. The company, which specializes in immunomodulatory cardiovascular therapies, reported quarterly EPS of ($0.09) and has an average target price of $9.00 from analysts, indicating", "url": "https://www.marketbeat.com/instant-alerts/cardiol-therapeutics-nasdaqcrdl-raised-to-strong-buy-at-brookline-capital-management-2026-02-05/", "source_name": "MarketBeat", "published_at": "2026-02-06T14:52:19", "published_display": "06 Feb 2026 14:52", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders", "summary": "Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the compa", "url": "https://finance.yahoo.com/news/cardiol-therapeutics-reports-results-2025-112700680.html", "source_name": "Market source", "published_at": "2026-02-01T00:32:36", "published_display": "01 Feb 2026 00:32", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing", "summary": "Cardiol Therapeutics has secured approximately $14.85 million through a bought-deal private placement. The financing involves issuing 11.4 million units at $1.30 per unit, each including one common share and a half-warrant exercisable at $1.75. This move aims to strengthen the co", "url": "https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-secures-14-85-million-bought-deal-unit-financing", "source_name": "TipRanks", "published_at": "2026-01-29T11:27:58", "published_display": "29 Jan 2026 11:27", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOTW1hcHZDMzN4dEU1TmNEcFJ0cnZsMVo3eUJONmZxMWoyM1BsWXlzUEdDRFQ1RjktMy0xRVdXcWJKWXJmSzE3RmgtYnhSaGhNYVRkWC10QVZLOU9WMVo5ekxHZUlBUkIydlRwSndKOVZVbUhTSnI0RzMxR1pucldmX1BvbnlHdjV0NXVTYnJnU0thdGNHMUJZ?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQd2JTakl5dzA3czNfYVctbUJUTDMwMzBDY0c2eVc3T1NMczBfaFd1eFVDMEc2R21CdENmSEZPdGlMdFhreTBOM3pEQktCNW5hTko5bzZZQXNqdTNzZzhwMFF6NEY2dFlXakJSYmhkVld4TkQ4SzN5U0U2dDRIRm40VlVweVlZWnpRUFE2eGRlMzJ5SGo5QlVyYkw4QnE4MWo5bm1oWTU0bmVpcnZWdXhkbG1pNFYzLWhfZ3VwekRBVmd6djJhSUdDRWQ1OWhVMFVVbkE?oc=5", "source_name": "TMX Newsfile", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 71, "total_relevant": 42, "sentiment_summary": {"positive": 14, "negative": 3, "neutral": 25, "score": 55, "total": 42, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.01, "latest_week": "2026-07-10", "one_week_move": -3.8, "four_week_move": -1.9, "twelve_week_move": -33.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.925403, "market_dynamics_buy_signal": false, "relative_strength": -23.027999, "fair_value_gap": -24.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.085, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.8% over one week, -1.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "CNW Group", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "TipRanks", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.8% over one week, -1.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com"}], "updated_at": "2026-07-16T02:16:36.032901+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}